Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 17/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 17/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809958 | 0.80 | CYP11B1 (0.47) | CYP11B1CYP11B2PRKACA | |
| SCHEMBL3159983 | 0.79 | TAAR1 (0.48) | — | |
| SCHEMBL2332730 | 0.78 | CYP11B2 (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL3166049 | 0.78 | CTSD (0.44) | CYP11B1CYP11B2 | |
| SCHEMBL14219369 | 0.77 | CYP11B1 (0.52) | CYP11B1CYP11B2 | |
| SCHEMBL14219545 | 0.77 | CYP11B1 (0.52) | CYP11B1CYP11B2 | |
| SCHEMBL30132416 | 0.76 | CYP11B1 (0.78) | CYP11B1CYP11B2 | |
| SCHEMBL1514257 | 0.76 | CYP11B1 (0.78) | CYP11B1CYP11B2 | |
| SCHEMBL8240319 | 0.75 | CYP11B2 (0.49) | CYP11B1CYP11B2 | |
| SCHEMBL3165716 | 0.75 | TUBB4A (0.44) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841504-B1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | TFPI, F3, F12 | CYP11B1 1182/4885CYP11B2 1361/4885PRKACA 1003/4885 |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | CYP11B1 1182/4885CYP11B2 1361/4885PRKACA 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.